CTIS2022-501910-79-01Active, not recruitingPhase 1
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)
Fondazione IRCCS Istituto Nazionale Dei Tumori0 sites73 target enrollmentStarted: February 15, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 73
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-BEJanssen-Cilag International NV140
Active, not recruiting
Phase 1
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-GBJanssen-Cilag International NV140
Active, not recruiting
Phase 1
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with JNJ-63723283 in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ESJanssen-Cilag International NV60
Active, not recruiting
Phase 1
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ITJANSSEN CILAG INTERNATIONAL NV140
Recruiting
Not Applicable
A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitorKCT0006051Yonsei University Health System, Severance Hospital44